Skip to content

Bioalmanac

PT-141

Bremelanotide · Vyleesi (brand)

Approved for another indication

Status reviewed 12 Aug 2026

A melanocortin receptor agonist approved by the FDA for low sexual desire in premenopausal women. It acts on the brain rather than on blood flow.

Storage

Freeze-dried powder
Refrigerated at 2–8 °C, protected from light.
After mixing
Refrigerated at 2–8 °C. Do not freeze once mixed.
Long-term, frozen
Unopened powder is stable at −20 °C or colder.

Reconstitution — 10 mg vial, 1750 mcg dose

On a 1 mL U-100 syringe. Check every figure against your own vial before drawing.

Water addedConcentrationVolume to drawUnitsDoses per vial
1 mL10 mg/mL0.175 mL17.5 units5.7
2 mL5 mg/mL0.35 mL35 units5.7
3 mL3.333 mg/mL0.525 mL52.5 units5.7
5 mL2 mg/mL0.875 mL87.5 units5.7

Dose ranges reported in sources

Descriptions of what sources report, not recommendations.

GoalRangeFrequencySource
Approved regimen for the licensed indication1750 mcgAs needed, no more than once in 24 hours and 8 times a monthClinical trial

When to stop

  • Chest pain, severe headache or visual disturbance after dosing. These can accompany a marked blood pressure rise. Seek urgent care.
  • Any allergic response: rash, hives, facial swelling or difficulty breathing. Seek urgent care.
  • Persistent nausea or vomiting that does not settle within hours.
  • New or spreading darkening of skin, gums or moles.
  • An erection lasting more than four hours is a medical emergency. Seek immediate care.

Approved by the FDA as a prescription medicine for hypoactive sexual desire disorder in premenopausal women. It is not approved for use in men, and material sold as a research chemical is not the approved product.

Arithmetic on values you enter. Not medical advice. Not reviewed by a clinician. · bioalmanac.com/peptides/pt-141

Use your browser’s print dialog and choose “Save as PDF”. This block is hidden when printed.